Clinical Programs Recent positive Phase 1 results for eganelisib in relapsed/refractory AML and higher-risk MDS with an ASCO 2026 presentation signal readiness to advance clinical programs; this creates sales opportunities in CRO and regulatory support, trial management, data analytics, and patient recruitment partnerships to accelerate potential Phase 2/3 discussions and licensing conversations.

Funding Momentum Stelexis is Deerfield-funded with a $43 million Series A in 2019, indicating strong investor backing and growth potential; with a lean team of 11-50 employees, there may be demand for outsourced services and strategic partnerships in CRO, contract manufacturing, and R&D support to scale operations.

Tech Enablement The technology stack shows a cloud-first, data-driven approach (AWS, S3, JSON-LD) and managed digital platforms (WordPress, Flywheel) plus security features; this alignment suggests opportunities to offer cloud hosting, data management and analytics platforms, regulated data integration, and cybersecurity or compliance services tailored to biotech needs.

Market Engagement Active participation in industry events like ASCO 2026 and NYC presence highlight opportunities for direct outreach to academic centers, KOLs, and potential licensees; sales focus could center on licensing discussions, collaboration agreements, investigator-initiated studies, and co-development partnerships.

Strategic Partnerships A focused oncology program with a small team creates a strong case for strategic alliances with CMOs for GMP manufacturing, translational research partners, and large pharma for licensing or co-development; there is also potential to monetize platform data and preclinical assets through targeted collaborations.